This is a pilot study to evaluate the role of the addition of CP870, 893 to the neoadjuvant
and adjuvant setting for patients with resectable pancreatic cancer. Patients will receive
standard surgery followed by chemoradiation for their disease, but one dose of gem/cp 870,893
will be pre-op and 3 doses post-op.